Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells

Abstract Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in Chronic Phase-Chronic Myeloid Leukaemia (CP-CML) cells constitute a unique model in terms of efficacy, specificity, and in vivo dem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marc G. Berger, Benjamin Lebecque, Thomas Tassin, Louis-Thomas Dannus, Juliette Berger, Mélanie Soucal, Agnès Guerci, Pascale Cony-Makhoul, Hyacinthe Johnson, Gabriel Etienne, Denis Guyotat, Marie-Claude Gagnieu, Bruno Pereira, Sandrine Saugues, Olivier Tournilhac, Eric Hermet, Céline Bourgne
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dba1f40c656e42c3b03434ba4b592551
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells

Ejemplares similares